Author Archives: admin

Global Stem Cells Group and Regenestem Network Announce Launch of New Stem Cell and Regenerative Medicine Clinic in …

By adminJanuary 29, 2015Stem Cell Treatment

MIAMI (PRWEB) January 29, 2015

Regenestem Network, the worlds largest membership network of regenerative medicine practitioners, has announced the launch of a new stem cell clinic in Oaxaca, Mexico. The new facility, offering the most advanced cellular medicine protocols and techniques available is in partnership with Ulises Cervera, M.D. a neurologist coming from the Children's Hospital of Morelia, Mexico.

The new Oaxaca facility will offer the most advanced protocols and techniques available in stem cell medicine to patients from across Mexico and around the world.

Global Stem Cells Group and Regenestem Network are expanding the companys clinical presence worldwide by partnering with experienced and qualified regenerative medicine physicians to open new clinics licensed and developed under the Regenestem banner.

In 2014, Global Stem Cells Group expanded the Regenestem Networks global presence to 20 countries.

Regenestem offers stem cell treatments to help treat a variety of diseases and conditions including arthritis, autism, chronic obstructive pulmonary disease (COPD), diabetes, and pain due to injuries at various facilities worldwide. Regenestem Oaxaca will have an international staff experienced in administering the latest in cellular therapies.

Regenestem is certified for the medical tourism market, and staff physicians are board-certified or board-eligible. Regenestem clinics provide services in more than 10 specialties, attracting patients from the United States and around the world.

The Global Stem Cells Group and Regenestem are committed to the highest of standards in service and technology, expert and compassionate care, and a philosophy of exceeding the expectations of their international patients.

For more information, visit the Regenestem Network website, email info(at)regenstem(dot)com, or call 305-224-1858.

About Regenestem: Regenestem Network, a division of the Global Stem Cells Group, Inc., is an international medical practice association committed to researching and producing comprehensive stem cell treatments for patients worldwide. Having assembled a highly qualified staff of medical specialistsprofessionals trained in the latest cutting-edge techniques in cellular medicineRegenestem continues to be a leader in delivering the latest protocols in the adult stem cell arena.

Link:
Global Stem Cells Group and Regenestem Network Announce Launch of New Stem Cell and Regenerative Medicine Clinic in ...

Epigenetic drug boosts chemotherapy's efficacy in some lung cancers

By adminJanuary 28, 2015Stem Cell Medicine

IMAGE:This is Carla Kim, PhD, of the Boston Children's Hospital Stem Cell Research Program. view more

Credit: Boston Children's Hospital

BOSTON (January 28, 2015) -- An existing drug may help some patients with non-small-cell lung cancer (NSCLC) whose tumors have become resistant to chemotherapy, finds a study from Boston Children's Hospital and the Dana-Farber Cancer Institute (DFCI). The findings, in human cancer cells and in mice, suggest a window of vulnerability in NSCLC, the leading cause of cancer-related deaths worldwide.1 The work was published online today by the journal Nature.

NSCLC is a highly genetically complex cancer with many different subtypes, each bearing different mutations. In two common subtypes that do not respond to standard chemotherapy--tumors with BRG1 or EGFR mutations--the researchers increased the effectiveness of etoposide, a common chemotherapy agent, by adding an epigenetic therapy already in clinical testing.

Conversely, when the same epigenetic therapy (inhibition of an enzyme known as EZH2) was added to certain tumors without BRG1 and EGFR mutations, the tumors become more resistant to chemotherapy. Together, the findings advance the idea of individualized, "precision medicine" in cancer, incorporating epigenetic therapy guided by tumor genetic testing.

The study also suggests that genetic tumor testing should screen for mutations in BRG1, a natural tumor suppressor. This test is not done widely now, although testing does look for EGFR mutations and other known cancer "driver" mutations. An estimated 10 percent of patients with NSCLC have BRG1 mutations, and this genetic subtype currently lacks a targeted therapy.

"Etoposide plus an EZH2 inhibitor could be a first-line therapy for BRG1-mutant tumors, and a treatment option for EGFR-mutant tumors that are resistant to tyrosine kinase inhibitors," says Christine Fillmore, PhD, of Boston Children's Hospital's Stem Cell Research Program, the study's first author.

EZH2 has been strongly linked with cancer progression and is part of a complex of molecules that determine which genes in a cell are turned "on" or "off"--part of the cell's so-called epigenome. Epigenetic therapy has become a hot area in cancer research, and EZH2 inhibitors are in phase I/II trials for other cancers, including B cell lymphomas and malignant rhabdoid tumors.

However, the use of EZH2 inhibitors in lung cancer has needed more rationale in preclinical studies, says oncologist Kwok-Kin Wong, MD, PhD, professor of medicine at DFCI and Harvard Medical School and a collaborator on the study. The researchers hope their findings will inspire the pharmaceutical industry to test EZH2 inhibitors together with chemotherapy in patients whose tumors have BRG1 or EGFR mutations.

"This study provides better predictive information as to which cancer patients will respond to EZH2 inhibitors, and shows that even epigenetic therapy needs to be specified to a genotype," says senior author Carla Kim, PhD, an associate professor at Boston Children's Stem Cell Program and the Department of Genetics at Harvard Medical School.

Read the rest here:
Epigenetic drug boosts chemotherapy's efficacy in some lung cancers

Arthritic knees three months after bone marrow stem cell therapy by Harry Adelson, N.D. – Video

By adminJanuary 28, 2015Uncategorized

Arthritic knees three months after bone marrow stem cell therapy by Harry Adelson, N.D.
Holly, three-time World Cup Downhill Gold Medalist and Olympian, discusses her outcome from bone marrow stem cells for her arthritic knees performed at Docere Clinics http://www.docereclinics.com.

By: Harry Adelson, N.D.

See more here:
Arthritic knees three months after bone marrow stem cell therapy by Harry Adelson, N.D. - Video

Experimental stem cell treatment key in Gordie Howes dramatic improvement

By adminJanuary 28, 2015Stem Cell Treatment

Gordie Howe has responded so well to stem cell treatment that his son Marty wants the Hockey Hall of Famer to undergo the procedure again.

Gordie suffered two strokes late last year and had maybe a month to live, Marty said, when his family took the 86-year-old to Mexico in December for the treatment.

Gordie Howe can walk again, his speech is improving and hes gained weight that he lost, according to his son.

He is doing so much better, Marty said Tuesday in Calgary. Its a joy to have him with us still.

Hopefully, in my mind, were going to have another treatment of this probably within two months.

Im actually hoping if he keeps doing what hes doing hell be able to travel again and maybe get to five or six events a year so people can see him another time.

Gordie Howe, known as Mr. Hockey, holds NHL records for most games played (1,767) and seasons played (26). He won the Stanley Cup four times as a Detroit Red Wing and also played for the Hartford Whalers.

His 801 career goals rank second only to Wayne Gretzkys 894.

Gordie Howe and Gretzky are scheduled to appear Feb. 6 in Saskatoon at a dinner, which Marty said will be a trial run on how his father responds to travel.

Marty Howe was in Calgary alongside NHL alumni Darryl Sittler, Marty McSorley and Lanny McDonald to promote a pro-am hockey tournament in Gordies name that raises money for Alzheimers and dementia research.

Stem Cells Could Treat Hair Loss

By adminJanuary 28, 2015Stem Cell Treatment

Got too much scalp? A new way to treat hair loss that doesnt involve solutions, creams or hocus-pocus could be on the way.

Scientists at the Sanford-Burnham Medical Research Institute have developed a stem cell method that initiates human hair growth.

Stem Cell Treatment Cures Blindness

Stem cells are the baseline, progenitor cells of all cells in our body. Using a genetic technique, Alexey Terskikh, an associate professor at the institute, and his colleagues coaxed stem cells to become dermal papilla cells.

These cells regulate the formation and growth cycle of hair follicles.

When transplanted into lab mice, the dermal papilla cells promoted the growth of hair.

Stem Cells Grow Beating Heart

Our next step is to transplant human dermal papilla cells derived from human pluripotent stem cells back into human subjects, said Terskikh. We are currently seeking partnerships to implement this final step.

Snake-oil salesmen need not apply.

via Sanford-Burnham Medical Research Institute

Read more here:
Stem Cells Could Treat Hair Loss

Opportunities in Human Embryonic Stem Cell (hESC) Products – Trends and Forecasts to 2017

By adminJanuary 27, 2015Stem Cell Medicine

LONDON, Jan. 27, 2015 /PRNewswire/ -- EXECUTIVE SUMMARY

Stem cells are primitive cells found in all multi-cellular organisms that are characterized by self-renewal and the capacity to differentiate into any mature cell type. Categorized by stage of life, several broad categories of stem cells exist, including:

- Embryonic stem cells, derived from blastocysts - Post-natal stem cells, derived from newborn tissues - Adult stem cells, found in adult tissues including hematopoietic stem cells, mesenchymal stem cells, neural stem cells, and more - Induced pluripotent stem cells, reprogrammed from adult cells - Cancer stem cells, which give rise to clonal populations of cells that form tumors or disperse in the body

Embryonic stem cells are stem cells derived from the inner cell mass of a blastocyst, which is a stage reached four to five days post-fertilization. They are the most pluripotent of all stem cell types and can develop into over 200 different cell types of the human body. Human embryonic stem cells (hESCs) were first derived from mouse embryos in 1981 by Martin Evans and Matthew Kaufman, and independently by Gail R. Martin. In 1995, the first successful culturing of embryonic stem cells from non-human primates occurred at the University of Wisconsin-Madison. Another breakthrough followed at the University of Wisconsin-Madison in November 1998 when a group led by Dr. James Thomson developed a technique to isolate and grow hESCs derived from human blastocysts. As such, embryonic stem cells are still a relatively new discovery, as the first mouse embryonic stem cells (ESCs) were derived from embryos in 1981, but it was not until 1995 that the first successful culturing of embryonic stem cells from non-human primates occurred and not until November 1998 that a technique was developed to isolate and grow embryonic stem cells from human blastocysts.

Market Segments

To facilitate research resulting from these advances, a large and diverse market has emerged for human embryonic stem cell products, platforms, and technologies. In total, the global sales of these items compose the hESC product marketplace. One thriving component of this marketplace is the segment of companies that sell hESC research products to scientists.

Termed "research supply companies" or "research product vendors," large companies selling human embryonic stem cell research products include Life Technologies, BD Biosciences, Thermo Fisher Scientific, EMD Millipore, Sigma Aldrich, Lonza, R&D Systems, and STEMCELL Technologies, as well as more than 60 other suppliers that range in size from multinational corporations to small specialty companies. Together, these research supply companies represent a substantial annual percentage of hESC product sales.

As of 2013, the following product categories accounted for more than 85% of all global hESC research product sales:

- Embryonic stem cell culture products - Embryonic stem cell lines - Antibodies to embryonic stem cell antigens - Bead-based embryonic stem cell separation systems - Embryonic stem cell protein purification and analysis tools - Tools for DNA and RNA-based characterization of embryonic stem cells - Embryonic stem cell specific growth factors and cytokines - Tools for embryonic stem cell gene regulation - Embryonic stem cell services and mechanisms for in vivo and in vitro stem cell tracking - In addition, pharmaceutical companies also have intense interest in human embryonic stem cell product development. Because of their plasticity and unlimited capacity for self-renewal, hESCs have been proposed for use in a wide range of pharmaceutical applications, including: - Drug target validation and testing - Toxicology testing - Tissue engineering - Cellular therapies - Personalized medicine - And more For this reason, development of hESC products by the pharmaceutical sector also represents a thriving segment of the global hESC product marketplace. Of particular interest to this community is the potential for use of hESCs to heal tissues that have a naturally limited capacity for renewal, such as the human heart, liver and brain. Furthermore, within the pharmaceutical sector, development of new drugs is extremely costly and the success rate of bringing new compounds to the market is unpredictable. Therefore, it is crucial that pharmaceutical companies minimize late-stage product failures, such as suboptimal pharmacokinetic properties or unexpected toxicity, that can arise when candidate drugs enter the clinical testing stages.

To achieve this, it would be highly desirable to test candidate drugs using in vitro assays of high human relevance as early as possible. Because hESCs have the potential to differentiate into all of the mature cell types of the human body, they represent an ideal cell type from which to design such drug screening assays.

Read the original here:
Opportunities in Human Embryonic Stem Cell (hESC) Products - Trends and Forecasts to 2017

Researchers advance the science behind treating patients with corneal blindness

By adminJanuary 27, 2015Stem Cell Medical Center

LOS ANGELES (Jan. 27, 2015) - Researchers in the Cedars-Sinai Board of Governors Regenerative Medicine Institute have devised a novel way to generate transplantable corneal stem cells that may eventually benefit patients suffering from life-altering forms of blindness.

Scientists used human corneal cells to generate pluripotent stem cells that have a capacity to become virtually any body cell. Then, putting these cells on natural scaffolds, researcher's facilitated differentiation of these stem cells back to corneal cells.

"Our research shows that cells derived from corneal stem cells are attractive candidates for generating corneal cells in the laboratory," said Alexander Ljubimov, PhD, director of the Eye Program at the Board of Governors Regenerative Medicine Institute and principal investigator on this research study.

This research, published in the journal Stem Cells Translational Medicine, marks an important first step toward creating a bank of corneal stem cells that may potentially benefit patients who suffer from many forms of corneal blindness. The group is now working to optimize the process with National Institutes of Health funding.

Corneal deficiencies may have genetic or inflammatory roots or be caused by injuries, like burns to the skin in occupational accidents. They result in damage or death of stem cells that renew the outermost part of the cornea. If left untreated, they often cause compromised vision or blindness.

Over 150,000 Americans and more than 3 million individuals worldwide are affected by corneal blindness.

###

Study collaborators include Clive Svendsen, PhD, director of the Board of Governors Regenerative Medicine Institute and professor of biomedical sciences and medicine; Dhruv Sareen, PhD, director of the Induced Pluripotent Stem Cell Core and assistant professor of biomedical sciences; Mehrnoosh Saghizadeh, PhD, assistant professor of biomedical sciences; Yaron Rabinowitz, MD, director of the Division of Ophthalmology Research; and Vincent A. Funari, PhD, director of the Genomics Core and assistant professor of pediatrics.

Citation: Sareen D, Saghizadeh M, Ornelas L, et al. Differentiation of human limbal-derived induced pluripotent stem cells into limbal-like epithelium. Stem Cells Transl Med. 2014; 3(9):1002-12.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.

Read this article:
Researchers advance the science behind treating patients with corneal blindness

ESI BIO A Division of BioTime, Inc. Announces New UK Distribution Agreement with 2BScientific

By adminJanuary 27, 2015Stem Cell Clinic

ALAMEDA, Calif.--(BUSINESS WIRE)--ESI BIO, the stem cell products division of BioTime, Inc., announces that its cGMP and research grade stem cell lines, reagents and cell matrix products are now available in the UK and Ireland through 2BScientific Ltd.

ESI BIOs (esibio.com) research products are used by stem cell researchers around the world and include clinical and research grade human embryonic stem cells from ES Cell International (ESI) and HyStem hyaluronan-based hydrogel extracellular matrices. ESI BIO also provides unique PureStem Embryonic Progenitors, antibodies and small molecules for stem cell differentiation and reprogramming.

Jeffrey Janus, CEO at ESI BIO commented, "We are pleased to hear that 2BScientific would like to be our distributor in the UK market and we expect that we can build a strong partnership in the future." James Bernard, CEO of 2BScientific added, "2BScientific is excited to have signed a distribution agreement with ESI BIO to sell all of their stem cell products and services in the United Kingdom and Ireland. We are excited to offer their cell lines and supporting products for stem cell researchers."

About ESI BIO

ESI BIO - A Division of BioTime, Inc., markets and distributes stem cell related research products provided by BioTime and its subsidiary companies. Many of these products can be provided as a research grade or clinical grade, including ES Cell Internationals human embryonic stem cell lines and HyStem hyaluronan-based hydrogels produced under conditions designed to be compliant with principles of current Good Manufacturing Practices (cGMP), making them suitable for use in clinical research and regenerative medicine. ESI BIO's portfolio includes PureStem human embryonic progenitors, antibodies, and small molecules for stem cell differentiation and reprogramming. ESI BIO's mission is to develop innovative research products that help translate scientific discoveries to the clinic. ESI BIO facilities are located in La Jolla and Alameda, California. Learn more at http://www.esibio.com.

About 2B Scientific

2B Scientific is a specialist distributor of immunological reagents to the UK life science market. 2B Scientific takes a novel approach to life science reagents distribution and provides a wide range of products including antibodies, PCR and flow cytometry reagents, apoptosis assays, proteins and life science consumables. Learn more at http://www.2BScientific.com.

Gordie Howes health improved dramatically after stem cell treatment

By adminJanuary 27, 2015Stem Cell Treatment

CALGARY They call it the miracle of stem cells and it was nothing less than a miracle says Marty Howe about his dad Gordies recovery.

Ata press conference Tuesday in Calgary for the Gordie Howe C.A.R.E.S annual hockey Pro-AM, Marty Howe talked about how the stem cell treatment saved Gordie Howes life after suffering two strokes.

He probably had a month to live the way he was going, he was deteriorating pretty fast. To have him now back and be able to relate to everybody really helps, Marty Howe said.

The Howe family remains positive and believes Gordie might be able to travel again and attend events soon. Marty Howe said his dad is already planning to attend an event in Saskatoon next month.

He can walk, hes got a sense of freedom now. He can play with the grand kids. He still needs to work with his speech, he cant sign yet but hopefully in the future he will be able to, Howe said.

Its a joy to have him with us still. Its nothing more of a gift. Hes down in Texas with my sister and we have caregivers that have been coming in for the past two and a half years too.

Gordie Howe has aform of dementia and the 86-year-old suffered hismost recent stroke just before Christmas last year due to dehydration.

A group of doctors, who happened to be named Howe, contacted the family and told them about a stem cell treatment they could offer for Gordie Howe. So the family went down to Mexico to give it a try.

Gordies health improved dramatically. Soon after, hewas able to walk and speak again. The family says Gordie plans to do asecond treatment in two months.

Known as Mr. Hockey, Howe was the NHLs Most Valuable Player six times. He played on four Stanley Cup championship teams in Detroit during a 25-year stint that began in 1946. The league scoring records he set stood until Wayne Gretzky broke them.

View original post here:
Gordie Howes health improved dramatically after stem cell treatment

Keeping the Kraken asleep

By adminJanuary 27, 2015Stem Cell Treatment

IMAGE:CDK6 is needed for leukemic stem cell activation (left). When CDK6 is absent, the LSC remains in a quiescent state and leukemia formation is prohibited (right). view more

Credit: Angelika Berger / Vetmeduni Vienna

Despite enormous progress in cancer therapy, many patients still relapse because their treatment addresses the symptoms of the disease rather than the cause, the so-called stem cells. Work in the group of Veronika Sexl at the University of Veterinary Medicine, Vienna has given a tantalizing clue to a solution. In the current issue of Blood, the scientists report that the cell-cycle kinase CDK6 is required for activation of the stem cells responsible for causing leukemia.

Hematopoietic stem cells (HSCs) are normally inactive, i.e. quiescent. When new blood cells are needed, for example to replace blood that has been lost, HSCs start to multiply and develop into mature blood cells. If the process is initiated at an inappropriate time, hematopoietic diseases such as leukemia may result and leukemic stem cells may develop. These represent a major challenge to leukemia therapy: they are quiescent and thus protected from elimination by the immune system and from treatment such as chemotherapy. Leukemic stem cells frequently cause relapse in cancer patients, often years or even decades after an apparently successful treatment.

Working with stem cells isolated from mice, Ruth Scheicher and colleagues at the University of Veterinary Medicine, Vienna have investigated possible differences between leukemic stem cells and the healthy stem cells in the body. They looked in particular at the function of the CDK6 protein, which is known to be involved in controlling the cell cycle. Surprisingly, CDK6 was also found to regulate the activation of hematopoietic and leukemic stem cells, which it does by inhibiting the transcription factor Egr1. Upon loss of CDK6, Egr1 becomes active and prevents stem cells from dividing. In a further twist to the tale, the mechanism operates only when hematopoietic stem cells are stressed, e.g. in leukemia, and not in the normal physiological situation.

Scheicher is quick to note the significance of her finding. "CDK6 is absolutely necessary for leukemic stem cells to induce disease but plays no part in normal hematopoiesis. We thus have a novel opportunity to target leukemia at its origin. Inhibiting CDK6 should attack leukemic stem cells while leaving healthy HSCs unaffected".

###

Service: The article 'CDK6 as a key regulator of hematopoietic and leukemic stem cell activation' by Scheicher R, Hoelbl-Kovacic A, Bellutti F, Tigan AS, Prchal-Murphy M, Heller G, Schneckenleithner C, Salazar-Roa M, Zchbauer-Mller S, Zuber J, Malumbres M, Kollmann K and Sexl V. was published in the journal Blood. http://www.bloodjournal.org/content/125/1/90.long?sso-checked=true

About the University of Veterinary Medicine, Vienna

The University of Veterinary Medicine, Vienna in Austria is one of the leading academic and research institutions in the field of Veterinary Sciences in Europe. About 1,300 employees and 2,300 students work on the campus in the north of Vienna which also houses five university clinics and various research sites. Outside of Vienna the university operates Teaching and Research Farms. http://www.vetmeduni.ac.at

See the article here:
Keeping the Kraken asleep